MétaCan
ENFR
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

Export CSVExport JSONAPI query

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Ovarian cancer diagnosis and treatment
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

2,301 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
2,301 works in the cohort · of 4,299,418page 9 of 47

Labels cover 7 of 2,301 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 2,301 of 2,301 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affunlabeled
Ovarian cancer
Christa L.P. Slatnik, Elsie Duff
2015· article· en· The Nurse Practitioner· Medicine
machine prediction:candidate · noneconsensus · none
56
citations
affno abstractunlabeled
EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer
Rebecca C. Arend, Allison M. Davis, Przemyslaw Chimiczewski, David M. O’Malley, Diane Provencher, Ignace Vergote +2 more
2019· article· en· Gynecologic Oncology· Medicine
machine prediction:candidate · noneconsensus · none
53
citations
affvenueno abstractunlabeled
Hyperreactio Luteinalis: Maternal and Fetal Effects
Ann Kinga Malinowski, Jonathan Sen, Mathew Sermer
2015· review· en· Journal of Obstetrics and Gynaecology Canada· Medicine
machine prediction:candidate · noneconsensus · none
50
citations
← previousnext →

How this was built: Screen · Findings · About